Sanger sequencing is a first-generation sequencing method, pioneered by Frederick Sanger. The key to this method is the use of dideoxy triphosphate nucleotide (ddNTP). DNA polymerase terminates the reaction in the chain extension process due to the addition of different ddNTP with fluorescent labels, which lack the hydroxyl group necessary for nucleotide binding. The ultimate identification of each nucleotide is achieved by counting DNA fragments with different lengths and different fluorescent labels.
Fig.1 The principle of Sanger sequencing. (Shendure, et al., 2017)
Currently, Sanger sequencing typically supports generating DNA sequences up to 800-1000 bp. The continuous development of various analysis software makes it convenient for data analysis. The cost of Sanger sequencing has also fallen.
CD BioGlyco leverages sequencing- and fragment analysis-based RNA assays with powerful reagents and workflows to give you the key data you need to analyze glycogene expression. CD BioGlyco has a mature, high-throughput, and automated Sanger sequencing workflow. The main steps include: isolating RNA, sequence amplification, sequencing reaction, purification of products, electrophoresis, and data analysis.
Fig.2 Workflow of Sanger sequencing-based glycogene expression profiling. (CD BioGlyco)
With 99.99% accuracy, Sanger sequencing is used as the gold standard for many applications. With our support, you smoothly conduct your research on glycobiology and solve the challenges you encounter.
CD BioGlyco is proud to quickly generate high-quality and publication-ready data to support your research in glycobiology. We offer a variety of Glycogene Expression Profiling Services and Caner Glycogene Discovery Services for you. Please feel free to contact us and we will reply to you as soon as possible.
Reference
About Us
CD BioGlyco is a leading biotechnology company specializing in glycobiology. We deliver high-quality products and services to support cutting-edge research worldwide.